1. Treatment of isolated tricuspid regurgitation in 2020: an update
- Author
-
Michele De Bonis, Ottavio Alfieri, Alessandro Verzini, Paolo Denti, Benedetto Del Forno, Giuseppe Iaci, Alessandro Castiglioni, Guido Ascione, Davide Carino, Elisabetta Lapenna, Davide Schiavi, Arturo Bisogno, Ascione, Guido, Del Forno, Benedetto, Carino, Davide, Lapenna, Elisabetta, Schiavi, Davide, Denti, Paolo, Bisogno, Arturo, Verzini, Alessandro, Iaci, Giuseppe, Alfieri, Ottavio, Castiglioni, Alessandro, and De Bonis, Michele
- Subjects
medicine.medical_specialty ,Percutaneous ,business.industry ,percutaneous treatment ,Review Article ,Regurgitation (circulation) ,Surgical correction ,medicine.disease ,Right ventricular dysfunction ,Surgical risk ,Liver disease ,Internal medicine ,cardiovascular system ,medicine ,Cardiology ,trans-catheter therapy ,cardiovascular diseases ,Tricuspid Valve Regurgitation ,Tricuspid valve regurgitation ,business ,Kidney disease - Abstract
Tricuspid valve regurgitation is an insidious pathology that is associated with increased mortality if left untreated. Conversely, surgical correction of tricuspid regurgitation is burdened by poor outcomes, especially when right ventricular dysfunction, kidney disease, or liver disease occur. There is, therefore, increasing interest in transcatheter approaches as an alternative to surgery in patients at high or prohibitive surgical risk. The development of percutaneous devices to treat tricuspid regurgitation has several technical challenges, mainly because of the complexity of valve anatomy, thus requiring accurate patient selection. Here we review the currently available transcatheter approaches to treat severe tricuspid regurgitation.
- Published
- 2020
- Full Text
- View/download PDF